China As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as the population ages, that number is expected to climb. A new report from Selesta looks at the country’s current standards…
APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to…
APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in…
See our Cookie Privacy Policy Here
